INTRODUCTION
Apoptosis is an essential process in the development of multicellular organisms, in the maintenance of tissue homeostasis, and in stress response. Previously, c-Abl was identified as a transducer in the process of apoptosis in response to DNA damage. c-Abl, a 140 kDa proto-oncoprotein, is a member of the Src family of nonreceptor tyrosine kinases and is ubiquitously expressed in cells. In addition to its kinase domain, c-Abl contains an SH2 domain with high affinity for phosphorylated tyrosine residues and an SH3 domain that mediates protein-protein interactions. The long C-terminal tail of c-Abl contains a putative DNA-binding domain with three high-mobility group-like domains and an actin-binding domain (reviewed in Shaul and Ben-Yehoyada, 2005) . c-Abl shuttles between the cytoplasm and nucleus, a process that is regulated by three nuclear localization signals (NLSs) and a single nuclear export signal (NES) motif (Taagepera et al., 1998) . Given the fact that the c-Abl NES is buried within a hydrophobic core structure of the actinbinding domain, its mode of action is debatable (Hantschel et al., 2005) . Under normal conditions when c-Abl is inactive, it is sequestered into the cytoplasm by binding to the 14-3-3 protein. Upon DNA damage, c-Jun N-terminal kinase (JNK) is activated, which in turn phosphorylates 14-3-3 at the binding site to c-Abl, which results in c-Abl release and localization to the nucleus (Yoshida et al., 2005) . In the nucleus, c-Abl is activated by phosphorylation of S465 by ATM (Bakkenist and Kastan, 2003; Baskaran et al., 1997) .
The molecular basis of the proapoptotic role of c-Abl has not yet been completely resolved. Initially it was suggested that p53 is a downstream and a central effector of c-Abl in this pathway. However, p53 was not found to be a c-Abl phosphorylation substrate (Ben-Yehoyada et al., 2003) . c-Abl, however, can affect p53 function in an indirect manner via phosphorylation of Mdm2 at Y394, which impairs its role in ubiquitin-dependent degradation of p53 (Goldberg et al., 2002) .
p73, a p53 paralog, was reported to be a more direct target of c-Abl. p73 induces apoptosis in a variety of cell lines and supports transcription from promoters containing the p53-response element (Jost et al., 1997) . p73 interacts with the SH3 domain of c-Abl and is phosphorylated by c-Abl on Y99 both in vitro and in vivo (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . This modification is induced in response to DNA damage and is accompanied by p73 accumulation and induction of proapoptotic genes (Gong et al., 1999; Tsai and Yuan, 2003) . Acetylation of p73 by p300, which relies on a c-Abl phosphorylation-induced association with Pin1, increases the transcriptional activation of the proapoptotic genes (Costanzo et al., 2002; Mantovani et al., 2004) .
Another important player in the pathway of c-Abl-p73 signaling is the Yes-associated protein (Yap1 or Yap65) that binds the SH3 domain of the Src family kinase c-Yes (Sudol, 1994) . Yap1 contains a proline-rich amino terminus, a WW domain, a coiled-coil, a PDZ, and an SH3-binding motif ( Figure 2A ) (Komuro et al., 2003; Strano et al., 2001; Sudol et al., 1995) . Yap1 lacks a known NLS, and its mechanism of nuclear entry is not well understood. Yap1 phosphorylated by Akt on S127 binds 14-3-3, an event that gives rise to Yap1 cytoplasmatic retention (Basu et al., 2003) . Therefore, the observed nuclear translocation of Yap1 in response to DNA damage (Strano et al., 2005) has to be regulated by an Akt inhibitory signal, similar to what has been observed with c-Abl.
Yap1 binds to p73 through its WW domain and the PPPY motif of p73 to serve as a p73 transcription coactivator (Strano et al., 2001) . In addition, this interaction rescues p73 from proteasomal degradation by preventing the association of p73 with the E3 ligase Itch, which also binds to p73 via a WW domain (Levy et al., 2007) . The DNA damage-induced stabilization of p73 is dependent on Yap1, as is the activation of apoptotic genes. It was shown that in addition to stabilization of p73, DNA damage by cisplatin treatment also leads to the accumulation of Yap1 (Levy et al., 2007) . In response to DNA damage, Yap1 is required to recruit the proteins p73 and p300 to proapoptotic genes in a selective manner (Strano et al., 2005) , but the underlying mechanism is not known. We show that Yap1 is a direct substrate of c-Abl and in response to DNA damage stress becomes phosphorylated at position Y357. Yap1 is a very labile protein; however, DNA damage stabilizes Yap1 in a c-Abl kinase-dependent manner. We also show that phosphorylated Yap1 binds to p73 with higher affinity and is selectively recruited onto the Bax promoter to induce apoptosis. Thus, our data attribute to phosphorylation of Yap1 by c-Abl a role of decision-making that determines cell fate.
RESULTS
c-Abl Stabilizes Yap1 in a Kinase-Dependent Manner Previously we noted that cisplatin increases the level of Yap1 (Levy et al., 2007) . Because cisplatin activates c-Abl as well, we explored the effect of c-Abl on Yap1 accumulation. HEK293 cells were transfected with a constant amount of Flag-tagged Yap1 and with an increasing amount of constitutively active c-Abl (D1-81) that expresses N-terminally truncated c-Abl (Pluk et al., 2002) . Immunoblot analysis revealed that the level of Yap1 increased in direct correlation with the level of c-Abl ( Figure 1A) . Accumulation of Yap1 was in direct correlation with D1-81 c-Abl expression, and c-Abl knockdown resulted in a sharp reduction in the Yap1 protein level ( Figure 1B) . Furthermore, Yap1 accumulation requires kinase competent c-Abl because the kinase dead c-Abl (km) mutant failed to increase Yap1 level ( Figure 1C ). Next, we measured Yap1 protein half-life in the presence or absence of cotransfected c-Abl in cycloheximide (CHX)-treated cells. Following cycloheximide addition, the level of Yap1 dropped dramatically within 3 hr ( Figure 1D ), suggesting that Yap1 is a short-lived protein. However, overexpression of wildtype or constitutively active c-Abl stabilized Yap1 ( Figures 1D  and 1E ). We further confirmed the role of c-Abl in Yap1 stabilization by pulse-chase analysis in HEK293 cells ( Figure 1F ). These data suggest that c-Abl stabilizes Yap1.
To demonstrate that the endogenous c-Abl regulates Yap1 stability, cells were transfected with Flag-tagged Yap1 and treated with STI571 (Schindler et al., 2000) to inhibit the endogenous c-Abl kinase activity. In untreated cells Yap1 was detectable, whereas in STI571-treated cells the level of the transfected Yap1 was sharply reduced ( Figure 1G ). To correlate c-Abl activity with Yap1 level, we utilized the paired cell lines HCT116-2(1) and HCT116-3(6). The mismatch-repair-defective human cell line HCT116-2(1) lacks the MLH1 gene on chromosome 3 necessary for c-Abl activation, while the HCT116-3(6) cells have a functional MLH1 gene as a result of transfer of chromosome 3 (Boyer et al., 1995) . As predicted from our data, the endogenous level of Yap1 was much higher in the HCT116-3(6) cells with competent c-Abl ( Figure 1H ), whereas no changes in Yap1 mRNA level that was measured by RT-PCR were observed ( Figure 1I ). We measured the dependency of Yap1 level on c-Abl in the breast cancer MCF-7 cells as well. Knocking down of the endogenous c-Abl by stably expressing c-Abl-specific siRNA resulted in a more than 50% decrease in the level of Yap1 protein ( Figure 1J ). Taken together, these data suggest that c-Abl stabilizes Yap1 in a kinase-dependent manner.
c-Abl Phosphorylates Yap1 on Y357 In Vivo and In Vitro
Yap1 binds the SH3 domain of the Src family kinase c-Yes including that of c-Abl (Sudol, 1994) . To show that Yap1 is in physical interaction with full-length c-Abl, HEK293 cells were transfected to express Flag-tagged Yap1 together with WT c-Abl. Figure 2B demonstrates that full-length c-Abl coimmunoprecipitated with Yap1, showing that the two can associate in vivo. The YxxP motif located at residues 357-360 in the Yap1 protein ( Figure 2A ) serves as a consensus sequence for phosphorylation by c-Abl (Tsai and Yuan, 2003) . To test the possibility that Yap1 is a substrate of c-Abl and undergoes tyrosine phosphorylation at position Y357, we generated the Y357F Yap1 mutant. HEK293 cells were cotransfected with either WT Yap1 or the Y357F mutant together with a constitutive c-Abl construct (D1-81 c-Abl). Wild-type and Y357F mutant Yap1 were immunoprecipitated and analyzed by a phosphotyrosine-specific antibody. Yap1 was efficiently tyrosine phosphorylated ( Figure 2C ), suggesting that Yap1 is a possible c-Abl substrate. Significantly, the Y357F mutant Yap1 did not undergo phosphorylation despite its efficient expression. To further validate the phosphorylation of Yap1 on Y357, we raised an antibody recognizing the phospho-Y357 epitope (p-Y357). This antibody detected the specific phosphorylation on Y357 both in immunoprecipitated Yap1 and also in the total cell extract ( Figure 2C , a p-Y357 panels, and see Figure S1 available online). We used this antibody to show that knockdown by a specific c-Abl siRNA and not the control siRNA (pX) gave rise to significant reduction in Yap1 phosphorylation ( Figure 2D , lanes 2 and 3). To rule out siRNA off-target activity, we used a c-Abl mutant that is resistant to the siRNA (containing six silent mutations in the c-Abl sequence). The expression of the siRNA-resistant c-Abl mutant was not affected by the c-Abl siRNA, and Yap1 phosphorylation was likewise not reduced by the c-Abl siRNA when this mutant was used, demonstrating that the siRNA was indeed specific to c-Abl and did not possess off-target activity that independently affected Yap1 phosphorylation ( Figure 2D , lanes 4 and 5). To confirm that c-Abl is the kinase of Yap1, we utilized the c-Abl-specific inhibitor STI571 and found that Yap1 phosphorylation was sharply reduced ( Figure 2E ). This is due to specific inhibition of c-Abl by STI571, because a c-Abl T334I mutant that is refractory to STI571 (Gorre et al., 2001) completely recovered Yap1 phosphorylation ( Figure 2F ). These data suggest that Yap1 is phosphorylated by the endogenous c-Abl (see also below).
To show that c-Abl phosphorylates Yap1 directly, an in vitro kinase reaction was performed. WT Flag-Yap1 and Flag-Yap1 Y357F were immunoprecipitated from HEK293 cells and subjected to in vitro kinase assay using purified recombinant c-Abl (Recom.). Yap1 was phosphorylated by the recombinant c-Abl in an ATP-dependent manner, whereas under the same experimental conditions the Y357F mutant was not ( Figure 2G ). Next, we compared the c-Abl-induced stabilization of WT Yap1 to that of Yap1 Y357F. In contrast to WT Yap1 that was stabilized by WT c-Abl in a dose-dependent manner, the Yap1 Y357F mutant, which cannot be phosphorylated by c-Abl, was not ( Figure 2H ). Furthermore, the half-life of the Y357F mutant, as measured by decay of the protein following CHX treatment, was not affected by constitutively active c-Abl ( Figure 2I ). Finally, we confirmed c-Abl-mediated Yap1 stabilization by pulse-chase analysis ( Figure 2J ). We concluded that Yap1 phosphorylation by c-Abl gives rise to Yap1 stabilization.
DNA Damage Induces Yap1 Phosphorylation and Stabilization by c-Abl
DNA damage is known to activate c-Abl kinase activity (Shaul and Ben-Yehoyada, 2005) . Our next objective was to determine whether DNA damage leads to c-Abl phosphorylation of Yap1. HEK293 cells overexpressing Yap1 and WT c-Abl that were exposed to g irradiation ( Figure 3A) show a significant elevation in the phosphorylation state of Yap1 at position Y357. As expected, treating the cells with STI571 on top of the IR treatment completely abolished Yap1 phosphorylation, and this correlated with Yap1 protein stabilization ( Figure 3A, lanes 3 and 4) .
To examine whether DNA damage can induce endogenous were g irradiated and subjected to immunoblot analysis using anti-pY357 antibody. Endogenous Yap1 was considerably phosphorylated to give rise to Yap1 stabilization ( Figure 3B ). In addition, endogenous Yap1 was phosphorylated and stabilized in cisplatin-treated HEK293 and H1299 cells in an STI571-sensitive manner ( Figure 3C ). Furthermore, examination of the subcellular localization of endogenous phosphorylated Yap1 revealed an extensive phosphorylation of Yap1 in the nuclear fraction after cisplatin treatment ( Figure 3D ). These data indicate that DNA damage induces endogenous Yap1 phosphorylation and stabilization by c-Abl.
p73 Preferentially Binds to Phosphorylated Yap1
Yap1 binds in vitro and in vivo to p73 through its WW domain and the PPPY motif of p73. In response to DNA damage, this interaction stabilizes p73 (Levy et al., 2007) and coactivates p73 function in transcription (Strano et al., 2001) . We next asked whether phosphorylated Yap1 preferentially binds to p73. Experiments with constitutively active c-Abl revealed that WT Yap1, but not the Y357F mutant, was efficiently coimmunoprecipitated with p73 ( Figure 4A ). In a reciprocal experiment, Flag-p73 was found to bind more strongly to the phosphorylated Yap1 (WT) than to the Y357F mutant ( Figure 4B Figure 4E ). The results indicate that the phosphomimetic Yap1 Y357E associated more strongly with p73 than did the Yap1 Y357F mutant.
Interestingly, inhibition of c-Abl kinase activity by STI571 resulted in decreased interaction between overexpressed WT Yap1 and the endogenous p73 ( Figure 4F ). Treatment with cisplatin dramatically increased the interaction between the transfected WT Yap1 and the endogenous p73, an interaction that was abolished by STI571 ( Figure 4G, lanes 2-4) . In contrast, the interaction of the Y357F mutant was not affected under these conditions, confirming the requirement of Yap1 phosphorylation by c-Abl. Finally, Figures 4H and 4I demonstrate that the interaction of endogenous p73 with endogenous Yap1 increased in response to g irradiation and was reduced by STI571 treatment in H1299 cells. These results suggest that Yap1 phosphorylation by c-Abl in response to DNA damage enhances the interaction with p73.
Yap1 is a known transcription modulator of Runx (Yagi et al., 1999) . The Runx family of transcription factors play important roles in development and in cell differentiation and proliferation (Coffman, 2003) . To test the possibility that tyrosine-phosphorylated Yap1 discriminates between p73 and Runx, we immunoprecipitated HA-Runx and HA-p73 from cells cotransfected with c-Abl (D1-81) in the presence or absence of Flag-Yap1 ( Figure 5 ). Flag-Yap1 was phosphorylated at position Y357 in the presence of active c-Abl to an equal level in both cases; cells transfected with HA-Runx or with HA-p73. Remarkably, however, while Yap1 coimmunoprecipitated with both Runx and p73, tyrosine-phosphorylated Yap1 was preferentially associated with p73. These results were also obtained with WT c-Abl ( Figure S2 ). These data further confirm the finding that tyrosinephosphorylated Yap1 shows selective association with p73.
Phosphorylated Yap1 Is Preferentially Recruited to Proapoptotic Promoters after DNA Damage
In response to DNA damage, overexpressed Yap1 and p73 are recruited to the Bax promoter to support transcription (Strano et al., 2005) . Having demonstrated that phosphorylated Yap1 selectively binds p73, we predicted preferential recruitment of the phosphorylated Yap1 onto p73 target genes. Chromatin immunoprecipitation (ChIP) analysis using HEK293T cells revealed that the association of endogenous Yap1 with the Bax promoter was increased in response to cisplatin ( Figure 6A , upper panel). Remarkably, treatment with STI571 revealed that the observed Yap1 association with the Bax promoter requires functional c-Abl. Indeed, ChIP analysis, using the specific phospho-Y357 Yap1 antibody, confirmed that modified Yap1 is in association with the promoters of the Bax and PIG3 genes. Similar results were obtained in H1299 cells ( Figure 6A, lower panel) . These data indicate that Yap1 phosphorylated by c-Abl is preferentially recruited onto the proapoptotic genes Bax and PIG3.
Because p73 mediates Yap1 recruitment to DNA, we investigated how DNA damage affects the binding of p73 to the Bax promoter. Surprisingly, although endogenous p73 was recruited to the Bax promoter after cisplatin treatment, this process was not affected by STI571 treatment ( Figure 6A ). Similar results were obtained in response to IR. HEK293T cells were g irradiated, and the occupancy of the Bax promoter was measured by real-time PCR ( Figure 6B ). These results confirmed that phosphorylated Yap1 and p73 were recruited to the Bax promoter in response to DNA damage. Using a pair of MCF-7 cell lines stably expressing a control shRNA or a c-Abl-specific shRNA (Figure 1J) , we demonstrated that under IR the recruitment of Yap1, but not p73, to the Bax promoter is c-Abl dependent ( Figure 6C ). Thus, c-Abl-mediated Bax activation is largely determined by phosphorylation of Yap1.
Yap1 imparts selectivity to p73 by promoting the activation of proapoptotic genes, but not the p21 cell-cycle-arrest gene (Strano et al., 2005) . We tested the possibility that the phosphorylation of Yap1 by c-Abl is the mechanism for the observed target gene se- lectivity. To this end, we used the ChIP experiments described above and found that both p73 and Yap1 were tightly associated with the p21 promoter ( Figure 6D ). However, while p73 association was unchanged by cisplatin or cisplatin/STI571 treatment, no Yap1 was detected on the p21 promoter after cisplatin. Remarkably, association of Yap1 with the p21 promoter was recovered by inhibiting c-Abl kinase activity, in an opposite manner to that seen with the Bax promoter. These data suggest that tyrosinephosphorylated Yap1 determines the p73 target gene selectivity toward the proapoptotic genes.
Osteocalcin (OC) is a known Runx-Yap1 target gene (Yagi et al., 1999) . To further examine the switching behavior of Yap1, we measured the association of endogenous Runx and Yap1 to the (OC) promoter in response to cisplatin treatment ( Figure 6E ). Interestingly, the (OC) gene-associated Yap1 could not be detected after treatment with cisplatin. Thus, tyrosine-phosphorylated Yap1 not only is selective in coactivating the p73 target genes but also in selecting the proper transcription factor.
Cisplatin-Induced Apoptosis Requires Phosphorylation of Yap1 by c-Abl
Knockdown experiments revealed that both Yap1 and c-Abl are important in Bax mRNA induction after cisplatin treatment ( Figure 7A) . A significant reduction in the level of apoptotic cells in response to cisplatin treatment was obtained in Yap1 knockdown H1299 cells ( Figure 7B ). These data and the fact that phosphorylated Yap1 preferentially binds p73 and is recruited onto the Bax promoter raised the possibility that Yap1 phosphorylation by c-Abl is important for induction of proapoptotic Bax expression. To substantiate this possibility, HEK293T cells were transfected with WT or Y357F Yap1 and the level of Bax transcript was analyzed by RT-PCR. The level of endogenous Bax transcript in untreated cells was undetectable; however, a significant increase in Bax mRNA level was observed upon cisplatin treatment ( Figure 7C ). This induction was reduced by overexpression of the Y357F Yap1 mutant, suggesting that this mutant behaves as a dominant negative or has a transcription-squelching effect ( Figure 7C and Figure S3 ).
To further study the effect of phosphorylated Yap1 on the transcription activation of Bax by p73, the Bax promoter-luciferase construct (Bax-Luc) was used to transfect H1299, a p53 null cell line ( Figure 7D ). Unlike the WT Yap1, the Y357 mutant failed to support p73 transcription activation of the Bax-Luc plasmid after cisplatin treatment. These results indicate that Yap1 phosphorylation by c-Abl improves Yap1 association and recruitment specifically to the Bax promoter with p73, resulting in increased transcription. In contrast, and consistent with our model, while WT Yap1 coactivated p73 in the context of the p21-Luc promoter, the phosphomimetic Yap1 Y357E did not ( Figure 7E ).
Next, we tested the contribution of phosphorylated Yap1 for the induction of apoptosis. H1299 cells were cotransfected with WT Yap1, Y357F mutant, and marker pEGFP-H2B plasmids and treated with cisplatin. The amount of GFP-positive cells undergoing apoptosis (sub-G1) was determined by FACS 48 hr after transfection. A significant increase in the level of apoptotic cells in response to cisplatin treatment was obtained in cells expressing WT Yap1, but not in cells expressing the Y357F mutant ( Figure 7F ). Similar results were obtained with MCF-7 cells ( Figure 7G) . Notably, neither WT Yap1 nor the Y357F Yap1 mutant was functional in c-Abl knocked-down cells. These results suggest that in response to DNA damage c-Abl induces apoptosis by phosphorylating Yap1 and improving Yap1 association with the proapoptotic p73 target genes.
DISCUSSION
The signaling pathway has to reach a decision-making point. This rather intuitive notion demands to be understood at the mo- were transfected with wild-type Yap1 (WT) or mutant Yap1 Y357F and were treated as in (E). SD is calculated from at least three independent experiments. lecular level by identifying the decision makers. For example, in response to DNA damage, the p53 paralog p73 is phosphorylated by c-Abl to accumulate and to induce apoptosis (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . Given the fact that the cell growth-arrest genes are potential targets of p73 as well, the question of how the desired gene is selected has attracted much attention. Initially it has been proposed that p73 is selectively recruited to the proapoptotic genes provided p300 is functional to acetylate p73 (Costanzo et al., 2002) . Later, the role of Yap1 in the selective activation became evident provided PML is functional (Strano et al., 2005) . However, the signal that capacitates Yap1 to select the desired genes remained an enigma. We report here the unique action of c-Abl in this process. c-Abl, the upstream effector, not only potentiates p73 activity but also modifies Yap1, the p73 modulator, to preferentially associate with p73 by increasing their affinity and to select the proper p73 target genes. In addition, both p73 and Yap1 undergo c-Abl-dependent accumulation to ensure their function.
We show that Yap1 is tyrosine phosphorylated at position Y357 in vitro by recombinant c-Abl and in vivo by a constitutively active c-Abl or under physiological conditions whereby the endogenous c-Abl is active. The modified tyrosine with the consensus YxxP motif is found in the highly conserved region of Yap1 at the putative transcription activation domain (Figure 2A ). Given the fact that the Y357F mutant is not phosphorylated at any detectable level, we concluded that Y357 is the only residue phosphorylated by c-Abl.
Yap1 contains five different alternative spliced variants (Komuro et al., 2003; Sudol, 1994; Yagi et al., 1999 ). An isoform lacking the C terminus portion of the protein and expressed mainly in neuronal cells acts in a dominant-negative manner in inducing apoptosis (Hoshino et al., 2006) . Interestingly, this isoform lacks the c-Abl Y357 phosphorylation site, reinforcing the importance of the modified region in apoptosis.
Yap1 is a labile protein but it is stabilized upon phosphorylation by c-Abl. Consistent with this finding is the fact that the specific kinase inhibitor of c-Abl, STI571, abolished endogenous Yap1 accumulation. A number of proteins are stabilized upon phosphorylation by c-Abl, such as p73 (Tsai and Yuan, 2003) and c-Jun (Barila et al., 2000) . The modified residue in c-Jun is positioned within a motif that binds the Itch E3 ligase (Gao et al., 2006) . No ubiquitin E3 ligase has been so far identified that associates with p73 at the region containing the Y99 modified residue. It has been shown that phosphorylation of p73 by c-Abl leads to its association with Pin1, which facilitates its acetylation and leads to its stabilization (Mantovani et al., 2004) . We have recently shown that Yap1 plays an important role in p73 stabilization, and this is independent of p73 phosphorylation by c-Abl (Levy et al., 2007) . Yap1 binds p73 via its WW domain and the p73 PPxY motif. The p73 PPxY motif also binds the WW domain of the Itch E3 ligase in the process of p73 degradation (Rossi et al., 2005) . Yap1 competes with Itch for binding to p73, which allows p73 to escape Itch-mediated ubiquitination (Levy et al., 2007) . Because we have shown that Yap1 is phosphorylated and stabilized as a result of c-Abl activation, and that tyrosine-phosphorylated Yap1 displays higher affinity toward p73, this is expected to improve the ability of p73 to escape Itch. Therefore, this is likely to represent another level of c-Abl involvement in p73 stabilization.
Our data provide evidence for redistribution of tyrosine-phosphorylated Yap1 in promoter occupation. Under normal, nonstress conditions, we could detect Yap1-p73 on the promoter of the p21 gene but not the proapoptotic Bax gene. However, an opposite situation was obtained in response to DNA damage stress, in a c-Abl kinase-dependent manner. In an attempt to understand this switching process, we investigated the role of phosphorylated Yap1. Our data demonstrate that Y-phosphoYap1 plays roles in selecting the transcription activator in one hand and the target genes in the other hand. Both Runx1 and p73 are known Yap1 interactors, but only the latter preferentially binds Y-phospho-Yap1. Y357 is positioned outside the WW domain of Yap1, the region responsible for interaction with p73, and therefore the basis for increased Yap1-p73 interaction following Y357 phosphorylation is not immediately clear. One possibility is that phosphorylation of Y357 leads to conformational changes in Yap1 that favor Yap1-p73 association. Pin1 binds phosphoproteins and conformationally modifies them by cis-trans isomerization of peptidyl-prolyl bonds. c-Abl enhances the phosphorylation-dependent interaction between Pin1 and p73, and this in turn promotes p73 acetylation by p300 (Mantovani et al., 2004) . Whether Pin1 plays a role in Yap1 interactions as well is an important question to be investigated.
In addition, we show that the phosphorylation state of Yap1 discriminates between p73 that binds p21 promoter versus p73 that binds Bax promoter. Previously, it has been reported that in response to DNA damage Yap1 is selectively recruited to the proapoptotic genes (Strano et al., 2005) ; however this Yap1 behavior was not correlated with its phosphorylation state. The fact that p53 selectively regulates certain promoters as a function of its activation in response to various stresses has been reported (Friedlander et al., 1996; Oda et al., 2000; Ryan and Vousden, 1998; Saller et al., 1999) . The underlying mechanisms remained to be clarified; however, in certain cases it has been attributed to the phosphorylation state of p53 (Oda et al., 2000; Saller et al., 1999) . No evidence is available for the involvement of Yap1 in the context of p53; therefore, the molecular mechanism described here is unique for p73 and possibly p63 (Strano et al., 2001) .
The mechanism of regulation of p21 by p73 and p53 is substantially different than that of Bax promoter. It has been reported that c-Abl improves p53 binding to the p21 promoter, but not the Bax promoter (Wei et al., 2005) . Using anti-c-Abl antibodies in ChIP experiments, we could detect c-Abl in association with p21 but not the Bax promoter (data not shown). However, p21 is activated by p73 in a c-Abl-independent manner (Costanzo et al., 2002) . Our results likewise demonstrate that p73 association with the p21 promoter is not affected by DNA damage, or by treatment with STI571. At the moment we do not know whether the p21 promoter-associated p73 is tyrosine phosphorylated, because of the lack of specific antibody to detect the endogenous tyrosine-phosphorylated p73. However, the fact that the level of the p21 promoter-associated p73 is not affected either by cisplatin treatment or by STI571 suggests that phosphorylation is not necessary for p73 to target the p21 promoter. In contrast, we show here that Yap1 targets the p21 gene provided that c-Abl is inactive. The preferred loading of nonphosphorylated Yap1-p73 complex on the p21 promoter demonstrates that Yap1 phosphorylation plays an important role in the switching from association with the p21 promoter to transcription of proapoptotic genes under DNA damage. It should be noted that at this point we cannot rule out the possibility that c-Abl remains associated with Yap1 following the phosphorylation event, and that this influences the interaction of Yap1 with p73 and Runx, and also impacts the target gene selection.
Overexpression of an active Src leads to phosphotyrosine Yap1 accumulation, but no attempts were made to show that this is a direct effect of Src and to identify the modified residue (Zaidi et al., 2004) . The sequence surrounding Y357 is very similar to other c-Abl substrates, which are distinct from those reported for Src (Songyang and Cantley, 1995) . Because Src À/À
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Phosphorylation of Yap1 by c-Abl osteoblasts exhibit accelerated differentiation and elevated levels of OC mRNA, it has been suggested that c-Src negatively regulates osteoblast maturation (Marzia et al., 2000; Thomas and Lafage-Proust, 1999) . This role of Src was explained by the capacity of Src to tyrosine phosphorylate Yap1 and to inhibit OC transcription, but the underlying molecular mechanism was not resolved. Similarly, mice that are deficient in Abl are osteoporotic and have defects in osteoblast maturation (Li et al., 2000) . Interestingly, Yap1 that is phosphorylated by c-Abl failed to be recruited to the OC promoter via Runx. Thus it is possible that the defect in osteoblast maturation in both cases is the result of Yap1 promoter switching in response to the action of nonreceptor tyrosine kinases. How a given protein is the substrate of a number of nonreceptor tyrosine kinases is an interesting question that has to be investigated in the future. In any case, the promoter-switching behavior of naive Yap versus the tyrosinephosphorylated protein appears to determine not only promoter selection in response to DNA damage but also the differentiation process.
In addition to the well-characterized proapoptotic role of Yap1, it also has a potential oncogenic role. Overexpression of Yap in MCF10A cells induces epithelial-to-mesenchymal transition, suppression of apoptosis, growth factor-independent proliferation, and anchorage-independent growth (Overholtzer et al., 2006) . Similarly, Yap1 amplification accelerates HCC tumorigenesis (Zender et al., 2006) . Consistently, overexpression of the Drosophila Yap ortholog yki results in proproliferative phenotype (Huang et al., 2005) . It is possible that Yap1 has a dual function determined by the nature of the target genes. As in Drosophila, Yap1 is a component of a proliferative signaling pathway that selectively coactivates promoters of proliferative genes. In animal cells, Yap1 coactivates the C-terminal fragment of proto-oncoprotein ErbB-4 (Komuro et al., 2003) . Thus, Yap1-p73 interaction and activity might represent a fail-safe mechanism to limit the oncogenic potential of Yap in the same way as apoptosis is obligatorily linked to oncogene activation (Huang et al., 2005 ). Given our model that Yap1 phosphorylation by c-Abl induces apoptosis, it is tempting to speculate that c-Abl switches between the potential proliferative and apoptotic target genes of Yap1.
EXPERIMENTAL PROCEDURES Cells and Cell Culture
The cell lines used were human embryonic kidney cells HEK293 and HEK293T, human colon-carcinoma lines HCT116-(2)1 and HCT116-(3)6 (Boyer et al., 1995) , human non-small cell lung carcinoma H1299 p53 null cells, human cervix adenocarcinoma HeLa cells, and human breast adenocarcinoma cell line MCF-7. Cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 8% fetal bovine serum (GIBCO), 100 units/ml penicillin, and 100 mg/ml streptomycin and cultured at 37 C in a humidified incubator with 5.6% CO 2 . H1299 cells were cultured under the same conditions with Roswell Park Memorial Institute (RPMI; GIBCO) medium. The MCF-7 and H1299 cell lines expressing stable pRetroSuper c-Abl siRNA and Yap1, respectively, were generated as described before (Brummelkamp et al., 2002a; Levy et al., 2007) .
Plasmids and Transfection
The plasmids used were as follows: pCMV Yap1 was a gift from M. Sudol; pCDNA HA-Yap1 and pCDNA Flag-Yap1 were subcloned by PCR and addition of EcoRI and NotI linkers. pCDNA HA-Yap1 Y357F and pCDNA Flag-Yap1 Y357F and Flag-Yap1 Y357E were constructed using site-directed mutagenesis. pSLX c-Abl D1-81 was kindly provided by G. Superti-Furga (Pluk et al., 2002) . pSG5 c-Abl WT and pSG5 km, R250H were described in Agami et al. (1999) . Bax-luc reporter plasmid was kindly provided by M. Oren. siRNA targeting Yap1 siRNA was described previously (Levy et al., 2007) . pSuper and pRetroSuper plasmids for the knockdown of c-Abl were prepared as described (Brummelkamp et al., 2002b) and targeted the following sequence: 5 0 -GACCAACTTGTTCAGCGCC-3 0 . The c-Abl mutant that is resistant to the siRNA has six silent mutations, which are indicated in small letters as follows: 5 0 -GACaAAtcTGTTtAGtGCt-3 0 . Empty pSuper plasmid, or the nonspecific plasmid pSuper X (Shlomai and Shaul, 2003) , encoding siRNA against HBV X protein was used for control. The STI571-resistant c-Abl 1b clone was prepared by site-directed mutagenesis to introduce the T334I mutation (corresponding to T315I mutation in c-Abl 1a previously described [Gorre et al., 2001] ). All transfections were done by the calcium phosphate method as described in Levy et al. (2007) . Flow cytometry and luciferase assays were done as previously described in Levy et al. (2007) .
Immunoblot and Coimmunoprecipitation Studies
Immunoblot, coimmunoprecipitation, half-life determination, and pulse-chase experiments were done as previously described in Asher et al. (2005) and Levy et al. (2007) . The antibodies used were anti-HA, monoclonal anti-b-tubulin, and anti-FLAG M5 (Sigma); polyclonal anti-Yap1 H125, anti-c-Abl K12, anti-phosphotyrosine p-Tyr (PY20), and anti-lamin-B M-20 (Santa Cruz Biotechnology); anti-p73 BL906 (Bethyl); and polyclonal antibodies to Y357-phosphorylated Yap1 that were generated in rabbits (Sigma) using a synthetic peptide corresponding to phospho-YAP1 (351-362) [p-Tyr357] [GLSMSSpYSVPRT-GC]. For immunizations, the peptides were conjugated via cysteine to maleimideactivated keyhole limpet hemocyanin (KLH). The antibodies were affinity purified using the peptide antigens coupled via cysteine to agarose beads (Sigma). In vitro kinase assays were done by using a recombinant c-Abl protein (NEB) according to the manufacturer's suggested reaction conditions. Subcellular fractionation procedure was slightly modified from Dignam et al. (1983) . Briefly, cells were swelled by suspension in hypotonic buffer followed by disruption of the cellular membrane by Dounce homogenization. The homogenate was centrifuged at 1000 3 g for 5 min. The supernatant was collected as a cytoplasmic extract. The pellet was washed three times and resuspended in nuclear extraction buffer added with 0.5% NP-40, 0.1% DOC, and 0.1% Brij.
Reverse Transcription and ChIP Analysis
RNAs were isolated and reverse transcribed as previously described in Lubelsky et al. (2005) . ChIP was performed according to the protocol of Ainbinder et al. (2002) . Briefly, formaldehyde crosslinked protein-DNA complexes were precipitated by incubation overnight with the indicated antibodies or with protein A beads (Pharmacia) for negative control. Precipitated DNA fragments were extracted with Chelex 100 resin (Bio-Rad) as described (Nelson et al., 2006) and amplified by PCR or real-time PCR (LightCycler 480, Roche, Gipf-Oberfrick, Switzerland) with specific primers. Primer sequences are available in the Supplemental Data.
Supplemental Data
Supplemental Data include three figures and one table and can be found with this article online at http://www.molecule.org/cgi/content/full/29/3/350/DC1/.
